Topical delgocitinib appears more effective than oral alitretinoin and is comparable to dupilumab for treating types of hand eczema, according to two separate studies.

A significant inverse association was observed among topical corticosteroid phobia and adherence to treatment among adults with chronic hand eczema.

Today, Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare ...

The European Commission (EC) has granted marketing authorisation to Leo Pharma ’s Anzupgo (delgocitinib) cream for treating ...

The European Commission has approved the topical pan–Janus kinase inhibitors inhibitor delgocitinib for adults with moderate ...

The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for delgocitinib cream as a treatment for moderate to severe chronic hand eczema in adults who have had an ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

Hand eczema, characterized by elevated skin pH and a compromised skin barrier, leaves hands susceptible to inflammation caused by external irritants. The issue is particularly prevalent among ...

LEO Pharma has presented late-breaking data on the DELTA FORCE trial for Anzupgo (delgocitinib) cream as a potential ...

FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema ...

Ballerup, Denmark Wednesday, September 25, 2024, 17:00 Hrs [IST] ...